サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1206484

欧州のECMO市場の2028年までの予測- 地域別分析- モダリティ、アプリケーション、年齢層別

Europe ECMO Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)
出版日: | 発行: The Insight Partners | ページ情報: 英文 126 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州のECMO市場の2028年までの予測- 地域別分析- モダリティ、アプリケーション、年齢層別
出版日: 2023年01月23日
発行: The Insight Partners
ページ情報: 英文 126 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州のECMO市場は、2022年の1億4,183万米ドルから2028年には1億6,697万米ドルに成長すると予測されています。2022年から2028年までのCAGRは2.8%を記録すると推定されています。

心血管疾患と呼吸不全の有病率の上昇が欧州のECMO市場を牽引する

体外式膜酸素療法（ECMO）は、心肺バイパス装置です。ECMO装置は、心血管系疾患や呼吸不全の治療に使用されます。欧州では毎年、心血管疾患（CVD）による数百万人の死亡が記録されています。CVDは欧州における死亡率と罹患率の主な原因となっており、欧州地域の死亡者の45％、欧州連合（EU）の死亡者の37％を占めています。慢性閉塞性肺疾患（COPD）は、肺からの空気の流れが阻害され、呼吸不全に陥ることがあります。地域全体で数百万人の死者を出す、生命を脅かす病気の一つです。世界保健機関（WHO）によると、2022年、COPDは死因の第3位となっています。COPDによる死亡の約90%は、低・中所得国で発生しています。したがって、心血管疾患と呼吸不全の有病率の増加は、欧州のECMO市場の成長を促進します。

欧州のECMO市場の概要

欧州のECMO市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。2022年はドイツが市場を独占心臓発作は、冠状動脈性心臓病（CHD）の最も深刻な結果です。360万人以上がCHDを患い、130万人以上が脳卒中から生還しています。ドイツでは、CHDの有病率が上昇しています。2020年に発表されたWHOの最新データによると、ドイツでは147,055人のCHDによる死亡が記録され、これは死亡者全体の20.98%に相当します。さらに、ドイツでは慢性閉塞性肺疾患（COPD）の有病率も高く、今後さらに増加することが予想されます。2020年の孤立型心臓移植は340件となり、前年比2.1％増となっています。しかし、分離肺移植は291件となり、6.4％の減少にとどまる。ECMOの使用は依然として増加しており、ECMOをほとんど行っていない病院も相当数あります。小規模病院では死亡率が有意に高かったが、病院規模とECMO死亡率の依存性は不規則でした。VV-ECMOはCOVID-19に関連した呼吸不全に罹患した患者に使用されました。体外生命維持（ECLS）または静脈動脈体外膜酸素化（VA-ECMO）と呼ばれる、心不全および循環不全における機械的支援のための体外循環の適用は、ドイツでは過去10年間に、2010年の<300例から2020年の2,852例に劇的に増加しました。COVID-19の発生時、ドイツでの病院内死亡率は68%でした。これは、他の国や国際的なレジストリが報告したものよりも著しく高いです。したがって、上記の要因は、予測期間中にECMO市場を強化することが期待されます。

欧州のECMO市場の収益と2028年までの予測（金額）

欧州のECMO市場のセグメント化

欧州のECMO市場は、モダリティ、アプリケーション、年齢層、国によって区分されます。

モダリティに基づき、欧州のECMO市場は静脈動脈性ECMO、静脈性ECMO、動静脈性ECMOに区分されます。2022年には、静脈動脈ECMOセグメントが最大の市場シェアを占めています。

アプリケーションに基づき、欧州のECMO市場は呼吸器系と循環器系に二分されます。2022年には呼吸器分野がより大きな市場シェアを占めました。

年齢層に基づき、欧州のECMO市場は成人、小児科、新生児に区分されます。2022年には成人セグメントが最も大きな市場シェアを占めました。

国別では、欧州のECMO市場は、英国、ドイツ、フランス、イタリア、スペイン、その他欧州に分類されます。地域別分析では、2022年にドイツが市場を独占しています。

ABIOMED Inc、Braile Biomedica、Eurosets S.R.L.、Fresenius Medical Care AG &Co KGaA、Getinge AB、LivaNova Plc、Medtronic Plc、MicroPort Scientific Corporation、Nipro Medical Corporation、およびTerumo Groupが、欧州のECMO市場で事業展開している主要企業です。

目次

第1章 イントロダクション

第2章 重要なポイント

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 欧州のECMO市場- 市場情勢

  • 欧州PEST分析
  • 専門家の見解

第5章 欧州のECMO市場-主要市場力学

  • 市場促進要因
    • 心血管疾患と呼吸不全の有病率の上昇
    • 肺移植術におけるECMOの採用の増加
  • 市場抑制要因
    • ECMOに関連する合併症
  • 市場機会
    • ECMO別生存率の向上
  • 今後の動向
    • 製品開発および承認の急増
  • インパクトのある分析

第6章 ECMO市場- 欧州の分析

  • 欧州のECMO市場の収益と予測・分析

第7章 欧州のECMO市場の分析：モダリティ別

  • 欧州のECMO市場：モダリティ別シェア 2021年・2028年（%）
  • 静脈性ECMO
  • 動静脈性ECMO
  • 動静脈ECMO

第8章 欧州のECMO市場の分析：アプリケーション別

  • 欧州のECMO市場：アプリケーション別2021年・2028年（%）
  • 呼吸器
  • 循環器

第9章 欧州のECMO市場の分析：年齢層別

  • 欧州のECMO市場：年齢層別、2021年・2028年（%）
  • 成人
  • 小児
  • 新生児

第10章 欧州のECMO市場：国別分析

    • 欧州
      • ドイツ
      • 英国
      • フランス
      • イタリア
      • スペイン
      • その他欧州

第11章 業界情勢

  • 無機的成長戦略
  • 有機的な成長戦略

第12章 企業プロファイル

  • Terumo Group
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • LivaNova Plc
  • Nipro Medical Corporation
  • Eurosets S.R.L.
  • Getinge AB
  • Braile Biomedica
  • Fresenius Medical Care AG & Co KGaA
  • ABIOMED Inc

第13章 付録

図表

List Of Tables

  • Table 1. Europe ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. Germany: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Germany: ECMO Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Germany: ECMO Market, by Age Group - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. UK: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. UK: ECMO Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. UK: ECMO Market, by Age Group - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. France: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. France: ECMO Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. France: ECMO Market, by Age Group - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Italy: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Italy: ECMO Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Italy: ECMO Market, by Age Group - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Spain: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Spain: ECMO Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Spain: ECMO Market, by Age Group - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Rest of Europe: ECMO Market, By Modality - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Rest of Europe: ECMO Market, by Application- Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Rest of Europe: ECMO Market, by Age Group- Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Recent Inorganic Growth Strategies
  • Table 21. Recent Organic Growth Strategies
  • Table 22. Glossary of Terms

List Of Figures

  • Figure 1. Europe ECMO Market Segmentation
  • Figure 2. Europe ECMO Market, By Country
  • Figure 3. Europe ECMO Market Overview
  • Figure 4. Europe ECMO Market, By Modality
  • Figure 5. Europe ECMO Market, By Country
  • Figure 7. Europe: PEST Analysis
  • Figure 8. Experts Opinion
  • Figure 9. Impact Analysis: Europe ECMO Market
  • Figure 10. Europe ECMO Market - Revenue Forecast and Analysis
  • Figure 11. Europe ECMO Market Share by Modality 2021 & 2028 (%)
  • Figure 12. Venoarterial ECMO: Europe ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 13. Venovenous ECMO: Europe ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 14. Arteriovenous ECMO: Europe ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 15. Europe ECMO Market, by Application 2021 & 2028 (%)
  • Figure 16. Respiratory : Europe ECMO Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 17. Cardiology : Europe ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 18. Europe ECMO Market, by Age Group 2021 & 2028 (%)
  • Figure 19. Adults : Europe ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 20. Pediatrics : Europe ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 21. Neonates : Europe ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 22. Europe: ECMO Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 23. Europe: ECMO Market, by Country, 2021 & 2028 (%)
  • Figure 24. Germany: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. UK: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. France: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Italy: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Spain: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Rest of Europe: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00027917

The Europe ECMO market is expected to grow from US$ 141.83 million in 2022 to US$ 166.97 million by 2028. It is estimated to record a CAGR of 2.8% from 2022 to 2028.

Rising Prevalence of Cardiovascular Diseases and Respiratory Failures Drives Europe ECMO Market

Extracorporeal membrane oxygenation (ECMO) is a heart-lungs bypass machine. ECMO equipment is used in the treatment of cardiovascular diseases and respiratory failures. Millions of deaths due to cardiovascular diseases (CVDs) are recorded every year across Europe. CVDs majorly cause mortality and morbidity in Europe, accounting for 45% of deaths in the region and 37% in the European Union (EU). Chronic obstructive pulmonary disease (COPD) causes obstruction in the airflow from the lungs, which can lead to respiratory failure. It is one of the life-threatening illnesses that cause millions of deaths across the region. According to World Health Organization (WHO), in 2022, COPD was the third leading cause of death. About 90% of COPD deaths occur in low- and middle-income countries. Therefore, the growing prevalence of cardiovascular diseases and respiratory failures drives the growth of the Europe ECMO market .

Europe ECMO Market Overview

The Europe ECMO market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million people suffer from CHD, and more than 1.3 million have survived a stroke. The prevalence of CHD is rising in Germany. According to the latest WHO data published in 2020, Germany recorded 147,055 CHD deaths, or 20.98% of total deaths. Moreover, chronic obstructive pulmonary disease (COPD) has a high prevalence rate in Germany, and a further increase is expected in the coming years. In 2020, the number of isolated heart transplantations increased to 340, a rise of 2.1% compared with the previous year. However, the isolated lung transplantations amounted to 291, a decrease of 6.4%. The use of ECMO is still increasing, and a substantial proportion of hospitals perform very few ECMO runs. Small hospitals had significantly higher mortality, but dependence on hospital size and ECMO mortality was irregular. VV-ECMO was used for patients affected by COVID-19-related respiratory failure. The applications of extracorporeal circulation for mechanical support in cardiac and circulatory failure, which are referred to as extracorporeal life support (ECLS) or veno-arterial extracorporeal membrane oxygenation (VA-ECMO), have dramatically increased over the past decade in Germany from <300 cases in 2010 to 2,852 in 2020. During COVID-19 outbreak, in-hospital mortality in Germany was 68%. This is markedly higher than that reported by other countries or international registries. Thus, the above factors are expected to bolster the ECMO market during the forecast period.

Europe ECMO Market Revenue and Forecast to 2028 (US$ Million)

Europe ECMO Market Segmentation

The Europe ECMO market is segmented based on modality, application, age group, and country.

Based on modality, the Europe ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.

Based on application, the Europe ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.

Based on age group, the Europe ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.

Based on country, the Europe ECMO market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany dominated the market in 2022.

ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the Europe ECMO market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe ECMO market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe ECMO market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the ECMO market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe ECMO Market - By Modality
    • 1.3.2 Europe ECMO Market - By Application
    • 1.3.3 Europe ECMO Market - By Age Group
    • 1.3.4 Europe ECMO Market - By Country

2. Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe ECMO Market - Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis
  • 4.3 Experts Opinion

5. Europe ECMO Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Cardiovascular Diseases and Respiratory Failures
    • 5.1.2 Growing Adoption of ECMO in Lung Transplantation Procedures
  • 5.2 Market Restraints
    • 5.2.1 Complications Associated with ECMO
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Survival Rates with ECMO
  • 5.4 Future Trends
    • 5.4.1 Surging Product Developments and Approvals
  • 5.5 Impact Analysis

6. ECMO Market - Europe Analysis

  • 6.1 Europe ECMO Market Revenue Forecast & Analysis

7. Europe ECMO Market Analysis - By Modality

  • 7.1 Overview
  • 7.2 Europe ECMO Market Share by Modality 2021 & 2028 (%)
  • 7.3 Venoarterial ECMO
    • 7.3.1 Overview
    • 7.3.2 Venoarterial ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Venovenous ECMO
    • 7.4.1 Overview
    • 7.4.2 Venovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Arteriovenous ECMO
    • 7.5.1 Overview
    • 7.5.2 Arteriovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)

8. Europe ECMO Market Analysis - By Application

  • 8.1 Overview
  • 8.2 Europe ECMO Market, By Application 2021 & 2028 (%)
  • 8.4 Respiratory
    • 8.4.1 Overview
    • 8.4.2 Respiratory Market Revenue and Forecast to 2028 (US$ Mn)
  • 8.5 Cardiology
    • 8.5.1 Overview
    • 8.5.2 Cardiology Market Revenue and Forecast to 2028 (US$ Mn)

9. Europe ECMO Market Analysis - By Age Group

  • 9.1 Overview
  • 9.2 Europe ECMO Market, By Age Group 2021 & 2028 (%)
  • 9.3 Adults
    • 9.3.1 Overview
    • 9.3.2 Adults Market Revenue and Forecast to 2028 (US$ Mn)
  • 9.4 Pediatrics
    • 9.4.1 Overview
    • 9.4.2 Pediatrics Market Revenue and Forecast to 2028 (US$ Mn)
  • 9.5 Neonates
    • 9.5.1 Overview
    • 9.5.2 Neonates Market Revenue and Forecast to 2028 (US$ Mn)

10. Europe ECMO Market - Country Analysis

  • 10.1 Overview
    • 10.1.2 Europe: ECMO Market, by Country, 2021 & 2028 (%)
      • 10.1.2.1 Germany: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.1.1 Overview
        • 10.1.2.1.2 Germany: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.1.3 Germany: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.1.4 Germany: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.1.5 Germany: ECMO Market, by Age Group, 2019-2028 (US$ Million)
      • 10.1.2.2 UK: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.2.1 Overview
        • 10.1.2.2.2 UK: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.2.3 UK: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.2.4 UK: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.2.5 UK: ECMO Market, by Age Group, 2019-2028 (US$ Million)
      • 10.1.2.3 France: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.3.1 Overview
        • 10.1.2.3.2 France: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.3.3 France: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.3.4 France: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.3.5 France: ECMO Market, by Age Group, 2019-2028 (US$ Million)
      • 10.1.2.4 Italy: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.4.1 Overview
        • 10.1.2.4.2 Italy: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.4.3 Italy: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.4.4 Italy: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.4.5 Italy: ECMO Market, by Age Group, 2019-2028 (US$ Million)
      • 10.1.2.5 Spain: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.5.1 Overview
        • 10.1.2.5.2 Spain: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.5.3 Spain: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.5.4 Spain: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.5.5 Spain: ECMO Market, by Age Group, 2019-2028 (US$ Million)
      • 10.1.2.6 Rest of Europe: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.6.1 Overview
        • 10.1.2.6.2 Rest of Europe: ECMO Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.2.6.3 Rest of Europe: ECMO Market, By Modality, 2019-2028 (US$ Million)
        • 10.1.2.6.4 Rest of Europe: ECMO Market, by Application, 2019-2028 (US$ Million)
        • 10.1.2.6.5 Rest of Europe: ECMO Market, by Age Group, 2019-2028 (US$ Million)

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Inorganic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Terumo Group
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Medtronic Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 MicroPort Scientific Corporation
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 LivaNova Plc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Nipro Medical Corporation
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Eurosets S.R.L.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Getinge AB
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Braile Biomedica
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Fresenius Medical Care AG & Co KGaA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 ABIOMED Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms